TIDMREDX
RNS Number : 2577H
Redx Pharma plc
14 November 2018
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY
THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER
THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF
THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN
REDX PHARMA PLC
("Redx" or "the Company")
Redx Pharma announces new drug development candidate for
fibrosis
RXC006, a novel, oral porcupine inhibitor, to be developed as a
first-in-class treatment for the orphan disease, idiopathic
pulmonary fibrosis
First-in-man studies earmarked for 2020
Pre-clinical data to be presented at the Anti-Fibrotic Drug
Development summit, Cambridge, USA on 29 November 2018
Alderley Park, 14 November 2018 Redx (AIM: REDX), the drug
discovery and development company focused on cancer and fibrosis,
is pleased to announce the nomination of its first development
compound to treat fibrosis. The new development candidate, RXC006,
is an oral porcupine inhibitor that will be developed as a
first-in-class treatment for the orphan disease, idiopathic
pulmonary fibrosis (IPF), a severe and life-threatening chronic
lung condition with very poor prognosis and limited treatment
options.
RXC006 represents a novel approach to treat this debilitating
and progressive disease through targeting porcupine, a component
enzyme of the Wnt pathway. There is strong scientific evidence that
this pathway is critically involved in the scarring process
(fibrosis) in the lung that is a hallmark of IPF.(1) This leads,
over time, to the lungs being unable to function effectively,
ultimately resulting in suffocation and death. Porcupine inhibition
suppresses the release of all Wnt ligands and therefore should
eliminate one of the major drivers of fibrosis in IPF. The median
survival from IPF diagnosis is 3 years and the annual incidence is
between 6.8-16.3/100,000 population in the U.S.(2)
Extensive pre-clinical testing has revealed that RXC006 is very
potent and highly effective at suppressing the Wnt pathway, and
hence fibrosis, in vivo in the lung as well as in the liver and the
kidney. Evidence shows that involvement of the Wnt pathway
increases with disease severity(3) and Redx believe that RXC006 may
also prove effective in more severe IPF patients where there is
currently no effective therapy beyond palliative care.
Lisa Anson, Chief Executive Officer at Redx Pharma plc
commented: "IPF is a devastating disease with little effective
treatment and there is, therefore, a clear unmet need for new
therapies. Redx is excited to bring its precision medicinal
chemistry expertise to bear with the discovery of this novel drug
candidate. We look forward to taking RXC006 into clinical
development; we plan to enter first in man clinical trials during
2020, in line with our strategy."
Dr. Peter Bunyard, Redx's Head of Fibrosis will be presenting
pre-clinical data at the 2(nd) Anti-Fibrotic Drug Development
summit in Cambridge USA on Thursday the 29(th) of November
2018.
For further information, please contact:
Redx Pharma Plc T: +44 1625 469
920
Lisa Anson, Chief Executive Officer
Richard Armer, Chief Scientific Officer
Cantor Fitzgerald Europe (Nominated Advisor & T: +44 20 7894
Joint Broker) 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20 3705
9330
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting T: +44 20 3727
1000
Simon Conway/Stephanie Cuthbert
About Redx Pharma Plc
Redx is a UK based biotechnology company whose shares are traded
on AIM (AIM:REDX). Redx's vision is to become a leading biotech
focused on the development of novel precision medicines that have
the potential to transform treatment in oncology and fibrotic
diseases.
If you would like to sign up to regular alerts from Redx Pharma,
please follow this link
https://www.redxpharma.com/investors/email-alerts/
About IPF
IPF is a life threatening fibrotic lung condition with diagnosed
prevalence projected to increase from 119,000 (2015) to 138,000
(2025). Current treatment options are OFEV(R)(nintedanib) and
Esbriet(R) (pirfenidone); both slow progression of disease by
approximately 50%. Product sales in IPF are projected to increase
from US$ 0.9b (2015) to US$3.2b (2025). (2)
About RXC006
Redx has invested into research to target the Wnt /ß-Catenin
signalling pathway by inhibition of the upstream porcupine enzyme
and has built considerable knowledge and expertise in this
scientific area. Our most advanced porcupine inhibitor, RXC004, is
currently being investigated clinically for the treatment of a
range of cancers. RXC006 is a potent porcupine inhibitor protected
by discrete Intellectual Property and has a predicted human PK
profile which will allow flexibility in dosing regimens to balance
efficacy with potential side effects. RXC006 is the first porcupine
inhibitor aimed at treating IPF.
References
1. Newman DR, Sills WS, Hanrahan K, Ziegler A, Tidd KM, Cook E, Sannes PL.
Expression of WNT5A in Idiopathic Pulmonary Fibrosis and Its
Control by TGF-<BETA> and WNT7B in Human Lung Fibroblasts. J
Histochem Cytochem. 2016 Feb;64(2):99-111.
2. Global Data Opportunity Analyser 2015, based on 7 major markets
3. Meuten T, Hickey A, Franklin K, Grossi B, Tobias J, Newman
DR, Jennings SH, Correa M, Sannes PL. WNT7B in fibroblastic foci of
idiopathic pulmonary fibrosis. Respir Res. 2012 Jul 28;13:62.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESBJBPTMBABBRP
(END) Dow Jones Newswires
November 14, 2018 02:00 ET (07:00 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024